The long-term course of chronic hepatitis B

Hepatology

Volumn 30, Issue 1, 1999, Pages 257-264

  Di Marco, Vito ^a   Lo Iacono, Oreste ^a   Cammà, Calogero ^b   Vaccaro, Alessandra ^a   Giunta, Marco ^a   Martorana, Giuseppe ^a   Fuschi, Patrizia ^a   Almasio, Piero L ^a   Craxì, Antonio ^a,c  

^a UNIVERSITY OF PALERMO   (Italy)

^b CNR   (Italy)

^c Istituto di Clinica Medica   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN;

ADOLESCENT; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASCITES; DISEASE COURSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HUMAN; JAUNDICE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SUPERINFECTION; SURVIVAL TIME; VIRUS REPLICATION;

ADOLESCENT; ADULT; AGED; ALCOHOLISM; CARCINOMA, HEPATOCELLULAR; CHILD; COHORT STUDIES; DISEASE-FREE SURVIVAL; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; ITALY; LIFE EXPECTANCY; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROBABILITY; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033002176     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510300109     Document Type: Article

References (24)

1. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. HEPATOLOGY 1988;8:493-496.
2. De Jongh FE, Janssen HLA, De Man RA, Hop WCJ, Schalm SW, Van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630-1635.
3. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, Christensen E, et al. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. HEPATOLOGY 1995;21:77-82.
4. Wong JB, Koff RS, Tiné E. Pauker SG. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995;122:664-675.
5. Perrillo RP, Aach RD. The clinical course and chronic sequelae of hepatitis B virus infection. Semin Liver Dis 1981;1:15-25.
6. Tine F, Liberati A, Craxì A, Almasio P, Pagliaro L. Interferon treatment in patients with chronic hepatitis B: a meta-analysis of the published literature. J Hepatol 1993;18:154-162.
7. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-323.
8. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991;114:629-634.
9. Carreño V, Castillo I, Molina J, Porres JC, Bartolome J. Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy. J Hepatol 1992;15:102-106.
10. Lok AS, Chung HT, Liu VW, Ma OC. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993;105:1833-1838.
11. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-1427.
12. Realdi G, Alberti A, Rugge M, Bortolotti F, Gigoli AM, Tremolada F, et al. Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology 1980;79:195-199.
13. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-a therapy: relationship to genotypes of hepatitis C virus. HEPATOLOGY 1992;16:293-299.
14. Scheuer, PJ. Classification of chronic hepatitis: a need for reassessment. J Hepatol 1991;13:372-374.
15. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV. Design and analysis of randomized clinical trials requiring prolonged observation. II. Analysis and examples. Br J Cancer 1977;35:1-39.
16. Cox DR. Regression models and life tables (with discussion). J Roy Statist Soc B 1972;34:187-220.
17. SAS Institute Inc. SAS guide for personal computers. Version 6.08. Cary, NC: SAS Institute Inc., 1988.
18. Schlichting P, Christensen E, Andersen PK, Fauerholdt L, Juhl E, Hemming P, Tygstrup N, et al. Prognostic factors in cirrhosis identified by Cox's regression model. HEPATOLOGY 1983;3:889-895.
19. Craxì A, Tine F, Vinci M, Almasio P, Cammà C, Garofalo G, Pagliaro L. Transmission of hepatitis B and hepatitis delta viruses in the households of chronic hepatitis B surface antigen carriers: a regression analysis of indicators of risk. Am J Epidemiol 1991;134:641-650.
20. Rothman KJ. Modern Epidemiology. Boston: Little, Brown & Co., 1986.
21. Jardi R, Buti M, Rodriguez-Frias F, Cortina M, Esteban R, Guardia J, Pascual C. The value of quantitative detection of HBV-DNA amplified by PCR is the study of hepatitis B infection. J Hepatol 1996;24:680-685.
22. Simpson PR, Yu XH, Redza ZM, Anson JG, Chan SU, Lin Y. Quantification of hepatitis B virus DNA using competitive PCR and a scintillation proximity assay. J Virol Methods 1997;69:197-208.
23. Gerken G, Gomes J, Lampertico P, Colombo M, Rothaar T, Trippler M, Colucci G. Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA PCR assay. J Virol Methods 1998;74:155-165.
24. Fong TL, Di Bisceglie AM, Waggoner JG, Banks SM, Hoofnagle JH. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B. HEPATOLOGY 1991;14:64-67.